Immunological Diagnostics

We aim at developing and evaluating new diagnostic, prognostic and therapeutic approaches for paediatric leukaemias using high-end multi-colour flow cytometry.

Biology of Leukaemias

Prof. Renate Panzer-Grümayer, MD
We are trying to understand why and how leukaemia evolves and use our knowledge to improve treatment and advance cure of affected children.

Genetics of Leukaemias

Sabine Strehl, PhD
Tracking down the faulty genes that cause leukaemia with the ultimate goal to establish predictive biomarkers for the optimisation of risk-adapted therapy.

Tumour Biology

Assoc. Prof. Peter F. Ambros, PhD
We aim to establish, validate and apply new diagnostic and therapeutic tools to facilitate personalised treatment of children with malignant tumours.

Molecular Biology of Solid Tumours

Prof. Heinrich Kovar, PhD
To increase therapeutic efficacy while decreasing side effects, we have to specifically target the Achille`s heel of the disease.

Epigenome-based precision medicine

Eleni M. Tomazou, PhD
The aim of our group is to establish an epigenome-based precision medicine program for pediatric sarcomas.

Development of Cellular Therapeutics

Prof. Wolfgang Holter, MD
Our group focuses on the development of therapeutic strategies based on T cells modified with chimeric antigen receptors (CARs). 

Clinical Cell Biology and FACS Core Unit

Assoc. Prof. René Geyeregger, PhD
With our engagement in flow cytometry and GMP-compliant work, we are a supportive interface between research and therapy.  

Molecular Microbiology

Prof. Thomas Lion, MD, PhD
Our group primarily focuses on the improvement of treatment outcomes, particularly in transplant recipients and patients with life-threatening infections, by developing and implementing new diagnostic technologies.  

Studies & Statistics for Integrated Research and Projects

Prof. Ruth Ladenstein, MD, MBA, cPM
Multinational networking is fundamental for clinical research of malignant cancer in children and adolescents. Only controlled large-scale clinical trials allow improving complex treatment strategies, whilst smaller studies allow testing innovative drug medications to further improve survival rates. The clinical trail unit S2IRP undertakes all efforts to serve the complex tasks of clinical trial management. 

Pathobiology of LCH

Caroline Hutter MD, PhD
The goal of our laboratory is to better understand the pathobiology of Langerhans Cell Histiocytosis (LCH) in order to develop new treatment approaches to the disease.

Innovative cancer models

Martin Distel, PhD
Our research focus is on the generation of pediatric cancer models in zebrafish to better understand tumor initiation and tumor progression on a cellular and molecular level. In addition, zebrafish disease models are applied in small compound screens to identify therapeutic compounds.